vs

Side-by-side financial comparison of ACCESS Newswire Inc. (ACCS) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $5.8M, roughly 1.1× ACCESS Newswire Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -9.9%, a 22.8% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs -0.5%). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 2.0%).

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years. The business was eventually sold to Western Union and then United Newspapers of London. In December 2015, Cision Inc. announced it would acquire the company. On January 1, 2021...

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

ACCS vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.1× larger
LCTX
$6.6M
$5.8M
ACCS
Growing faster (revenue YoY)
LCTX
LCTX
+130.9% gap
LCTX
130.4%
-0.5%
ACCS
Higher net margin
LCTX
LCTX
22.8% more per $
LCTX
12.9%
-9.9%
ACCS
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
2.0%
ACCS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACCS
ACCS
LCTX
LCTX
Revenue
$5.8M
$6.6M
Net Profit
$-576.0K
$851.0K
Gross Margin
77.4%
Operating Margin
-13.1%
-99.1%
Net Margin
-9.9%
12.9%
Revenue YoY
-0.5%
130.4%
Net Profit YoY
94.4%
126.0%
EPS (diluted)
$-0.16
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACCS
ACCS
LCTX
LCTX
Q4 25
$5.8M
$6.6M
Q3 25
$5.7M
$3.7M
Q2 25
$5.6M
$2.8M
Q1 25
$5.5M
$1.5M
Q4 24
$5.8M
$2.9M
Q3 24
$5.6M
$3.8M
Q2 24
$6.0M
$1.4M
Q1 24
$5.6M
$1.4M
Net Profit
ACCS
ACCS
LCTX
LCTX
Q4 25
$-576.0K
$851.0K
Q3 25
$-45.0K
$-29.8M
Q2 25
$-475.0K
$-30.5M
Q1 25
$5.4M
$-4.1M
Q4 24
$-10.2M
$-3.3M
Q3 24
$-466.0K
$-3.0M
Q2 24
$7.0K
$-5.8M
Q1 24
$-139.0K
$-6.5M
Gross Margin
ACCS
ACCS
LCTX
LCTX
Q4 25
77.4%
Q3 25
74.6%
Q2 25
76.2%
Q1 25
78.0%
97.6%
Q4 24
75.2%
94.6%
Q3 24
75.0%
99.0%
Q2 24
77.2%
96.9%
Q1 24
75.1%
93.2%
Operating Margin
ACCS
ACCS
LCTX
LCTX
Q4 25
-13.1%
-99.1%
Q3 25
-3.2%
-102.9%
Q2 25
-4.4%
-715.4%
Q1 25
-12.4%
-433.1%
Q4 24
-245.8%
-178.2%
Q3 24
-10.7%
-101.6%
Q2 24
-8.8%
-416.7%
Q1 24
-15.5%
-461.3%
Net Margin
ACCS
ACCS
LCTX
LCTX
Q4 25
-9.9%
12.9%
Q3 25
-0.8%
-809.0%
Q2 25
-8.5%
-1101.8%
Q1 25
98.4%
-275.6%
Q4 24
-175.0%
-114.1%
Q3 24
-8.3%
-80.3%
Q2 24
0.1%
-409.1%
Q1 24
-2.5%
-453.0%
EPS (diluted)
ACCS
ACCS
LCTX
LCTX
Q4 25
$-0.16
$0.00
Q3 25
$-0.01
$-0.13
Q2 25
$-0.12
$-0.13
Q1 25
$1.40
$-0.02
Q4 24
$-2.66
$0.00
Q3 24
$-0.12
$-0.02
Q2 24
$0.00
$-0.03
Q1 24
$-0.04
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACCS
ACCS
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$3.0M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$30.3M
$44.5M
Total Assets
$42.0M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACCS
ACCS
LCTX
LCTX
Q4 25
$3.0M
$55.8M
Q3 25
$3.3M
$40.5M
Q2 25
$42.3M
Q1 25
$47.9M
Q4 24
$4.1M
$47.8M
Q3 24
$32.7M
Q2 24
$38.5M
Q1 24
$43.6M
Stockholders' Equity
ACCS
ACCS
LCTX
LCTX
Q4 25
$30.3M
$44.5M
Q3 25
$30.8M
$22.0M
Q2 25
$30.7M
$48.4M
Q1 25
$30.9M
$79.0M
Q4 24
$25.2M
$78.4M
Q3 24
$35.3M
$66.2M
Q2 24
$35.4M
$68.3M
Q1 24
$35.2M
$72.4M
Total Assets
ACCS
ACCS
LCTX
LCTX
Q4 25
$42.0M
$112.6M
Q3 25
$44.0M
$89.6M
Q2 25
$45.6M
$90.8M
Q1 25
$47.3M
$111.8M
Q4 24
$50.6M
$113.2M
Q3 24
$61.7M
$96.6M
Q2 24
$62.8M
$102.8M
Q1 24
$64.4M
$108.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACCS
ACCS
LCTX
LCTX
Operating Cash FlowLast quarter
$258.0K
$-4.9M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
0.0%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACCS
ACCS
LCTX
LCTX
Q4 25
$258.0K
$-4.9M
Q3 25
$-582.0K
$-3.6M
Q2 25
$135.0K
$-5.5M
Q1 25
$747.0K
$-4.9M
Q4 24
$866.0K
$-6.3M
Q3 24
$1.5M
$-5.8M
Q2 24
$-190.0K
$-5.2M
Q1 24
$986.0K
$-5.8M
Free Cash Flow
ACCS
ACCS
LCTX
LCTX
Q4 25
$-5.3M
Q3 25
$-590.0K
$-3.6M
Q2 25
$-5.6M
Q1 25
$735.0K
$-5.0M
Q4 24
$-6.7M
Q3 24
$1.5M
$-5.9M
Q2 24
$-5.2M
Q1 24
$970.0K
$-5.8M
FCF Margin
ACCS
ACCS
LCTX
LCTX
Q4 25
-79.9%
Q3 25
-10.3%
-98.6%
Q2 25
-200.8%
Q1 25
13.4%
-331.8%
Q4 24
-234.0%
Q3 24
26.5%
-156.1%
Q2 24
-371.2%
Q1 24
17.4%
-403.1%
Capex Intensity
ACCS
ACCS
LCTX
LCTX
Q4 25
0.0%
6.0%
Q3 25
0.1%
0.3%
Q2 25
0.0%
0.5%
Q1 25
0.2%
6.5%
Q4 24
0.0%
12.7%
Q3 24
0.1%
3.0%
Q2 24
0.0%
3.6%
Q1 24
0.3%
2.6%
Cash Conversion
ACCS
ACCS
LCTX
LCTX
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
0.14×
Q4 24
Q3 24
Q2 24
-27.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACCS
ACCS

Cost To Deliver Products$3.1M54%
Employee Costs$1.7M29%
Other$1.0M17%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons